Kabra Drugs Intrinsic Value
Kabra Drugs (KABRADG) median intrinsic value is ₹29.17 from 8 valuation models (range ₹13–₹46), vs current price ₹22.84 — +27.7% upside (Trading Below Calculated Value), margin of safety 21.7%. Read Kabra Drugs dividend payments for the complete payout history and dividend yield track record.
KABRADG Valuation Methods Summary — DCF, Graham Number & P/E
Kabra Drugs intrinsic value across 8 models vs current price ₹22.84 — upside/downside and value range per method. Analyse Kabra Drugs ownership structure to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹45.98 | ₹36.78 - ₹55.18 | +101.3% | EPS: ₹2.09, Sector P/E: 22x |
| Book Value Method | asset | ₹25.00 | ₹22.50 - ₹27.50 | +9.5% | Book Value/Share: ₹12.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹45.68 | ₹41.11 - ₹50.25 | +100.0% | Revenue/Share: ₹38.75, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹20.83 | ₹18.75 - ₹22.91 | -8.8% | EBITDA: ₹5.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹13.38 | ₹12.04 - ₹14.72 | -41.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹32.29 | ₹29.06 - ₹35.52 | +41.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹29.17 | ₹26.25 - ₹32.09 | +27.7% | ROE: 16.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹24.24 | ₹21.82 - ₹26.66 | +6.1% | EPS: ₹2.09, BVPS: ₹12.50 |
KABRADG Intrinsic Value vs Market Price — All Valuation Models
Kabra Drugs fair value range ₹13–₹46 vs current market price ₹22.84 across 8 valuation models. For current market price and key ratios, visit Kabra Drugs share price chart.
KABRADG Intrinsic Value Analysis — Undervalued or Overvalued?
Kabra Drugs median intrinsic value ₹29.17, current price ₹22.84 — Trading Below Calculated Value by 27.7%, margin of safety 21.7%.
What is the intrinsic value of KABRADG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Kabra Drugs (KABRADG) is ₹29.17 (median value). With the current market price of ₹22.84, this represents a +27.7% variance from our estimated fair value.
The valuation range spans from ₹13.38 to ₹45.98, indicating ₹13.38 - ₹45.98.
Is KABRADG undervalued or overvalued?
Based on our multi-method analysis, Kabra Drugs (KABRADG) appears to be trading below calculated value by approximately 27.7%.
KABRADG Financial Health — Key Ratios vs Industry Benchmarks
Kabra Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 16.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.08x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KABRADG Cash Flow Quality — Operating & Free Cash Flow
Kabra Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |